Robin E Bachelder obtained her Ph.D. from Harvard University in 1995, and pursued Postdoctoral studies at Harvard Medical School for an additional 10 years. She joined the faculty in the Department of Pathology at Duke University School of Medicine in 2005, where she initiated her studies of triple-negative breast cancer chemotherapy resistance. Her research focuses on understanding tumor heterogeneity, and its implications for therapy resistance. She has published more than 20 peer-reviewed manuscripts, and is the recipient of multiple grants from the Department of Defense, National Institutes of Health, and private foundations. Robin E Bachelder obtained her Ph.D. from Harvard University in 1995, and pursued Postdoctoral studies at Harvard Medical School for an additional 10 years. She joined the faculty in the Department of Pathology at Duke University School of Medicine in 2005, where she initiated her studies of triple-negative breast cancer chemotherapy resistance. Her research focuses on understanding tumor heterogeneity, and its implications for therapy resistance. She has published more than 20 peer-reviewed manuscripts, and is the recipient of multiple grants from the Department of Defense, National Institutes of Health, and private foundations.

Genetics and Molecular Biology